Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images
- PMID: 36516847
- PMCID: PMC9798078
- DOI: 10.1016/j.xcrm.2022.100872
Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images
Abstract
Homologous recombination DNA-repair deficiency (HRD) is becoming a well-recognized marker of platinum salt and polyADP-ribose polymerase inhibitor chemotherapies in ovarian and breast cancers. While large-scale screening for HRD using genomic markers is logistically and economically challenging, stained tissue slides are routinely acquired in clinical practice. With the objectives of providing a robust deep-learning method for HRD prediction from tissue slides and identifying related morphological phenotypes, we first show that digital pathology workflows are sensitive to potential biases in the training set, then we propose a method to overcome the influence of these biases, and we develop an interpretation method capable of identifying complex phenotypes. Application to our carefully curated in-house dataset allows us to predict HRD with high accuracy (area under the receiver-operator characteristics curve 0.86) and to identify morphological phenotypes related to HRD. In particular, the presence of laminated fibrosis and clear tumor cells associated with HRD open new hypotheses regarding its phenotypic impact.
Keywords: bias; breast cancer; computational pathology; deep learning; homologous recombination deficiency; interpretability; molecular subtype; prediction; self-supervised learning; whole slide images.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.V.-S. is a member of the IBEX scientific advisory board. A.V.-S. has received a grant from AstraZeneca to support the technical work to prepare the series of breast cancers analyzed in this series. The authors have filed the patent with PCT application number PCT/EP2022/071130.
Figures





Comment in
-
HRD-related morphology discovery in breast cancer by controlling for confounding factors.Cell Rep Med. 2022 Dec 20;3(12):100873. doi: 10.1016/j.xcrm.2022.100873. Cell Rep Med. 2022. PMID: 36543118 Free PMC article.
References
-
- Deluche E., Antoine A., Bachelot T., Lardy-Cleaud A., Dieras V., Brain E., Debled M., Jacot W., Mouret-Reynier M.A., Goncalves A., et al. Contemporary outcomes of metastatic breast cancer among 22, 000 women from the multicentre ESME cohort 2008–2016. Eur. J. Cancer. 2020;129:60–70. doi: 10.1016/j.ejca.2020.01.016. - DOI - PubMed
-
- Miller R.E., Leary A., Scott C.L., Serra V., Lord C.J., Bowtell D., Chang D.K., Garsed D.W., Jonkers J., Ledermann J.A., et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann. Oncol. 2020;31:1606–1622. doi: 10.1016/j.annonc.2020.08.2102. - DOI - PubMed
-
- Tung N.M., Robson M.E., Ventz S., Santa-Maria C.A., Nanda R., Marcom P.K., Shah P.D., Ballinger T.J., Yang E.S., Vinayak S., et al. Tbcrc 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 2020;38:4274–4282. doi: 10.1200/JCO.20.02151. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical